70%Confidence
0Views
SEC EDGARSource
2026-03-09Date
Summary
Relmada Therapeutics filed a current report, likely disclosing material events such as clinical trial data or corporate governance changes for its depression treatments. Negative outcomes could pressure the stock, while positives may drive upside.
Actionable: Scrutinize the filing for trial updates or executive changes to reassess the company's risk-reward profile.
AI Confidence: 70%
Data Points
companyRELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643)
form8-K
date2026-03-09
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now